Evidence map›Paper›PMID 28422962›Full record

ArticlePloS one2017

Docosahexaenoic acid blocks progression of western diet-induced nonalcoholic steatohepatitis in obese Ldlr-/- mice.

Kelli A Lytle, Carmen P Wong, Donald B Jump

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Linking LOXL2 to Cardiac Interstitial Fibrosis.International journal of molecular sciences · 2020
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kelli A LytleNutrition Program, School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, United States of America.
Carmen P WongNutrition Program, School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, United States of America.
Donald B JumpNutrition Program, School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, United States of America.ORCID http://orcid.org/0000-0002-9473-6283
Oregon State University · US

Funding

PUFA Synthesis and the Control of Hepatic MetabolismR01DK094600 · NIDDK · OREGON STATE UNIVERSITY · PI JUMP, DONALD B · 2012 to 2015
$1.2M
NIDDK NIH HHS R01 DK094600
6 · The paper itself

Abstract

backgroundNonalcoholic fatty liver disease (NAFLD) is a major public health concern in western societies. Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, is characterized by hepatic steatosis, inflammation, oxidative stress and fibrosis. NASH is a risk factor for cirrhosis and hepatocellular carcinoma. NASH is predicted to be the leading cause of liver transplants by 2020. Despite this growing public health concern, there remain no Food and Drug Administration (FDA) approved NASH treatments. Using Ldlr -/- mice as a preclinical model of western diet (WD)-induced NASH, we previously established that dietary supplementation with docosahexaenoic acid (DHA, 22:6,ω3) attenuated WD-induced NASH in a prevention study. Herein, we evaluated the capacity of DHA supplementation of the WD and a low fat diet to fully reverse NASH in mice with pre-existing disease.

methodsLdlr -/- mice fed the WD for 22 wks developed metabolic syndrome (MetS) and a severe NASH phenotype, including obesity, dyslipidemia, hyperglycemia, hepatic steatosis, inflammation, fibrosis and low hepatic polyunsaturated fatty acid (PUFA) content. These mice were randomized to 5 groups: a baseline group (WDB, sacrificed at 22 wks) and 4 treatments: 1) WD + olive oil (WDO); 2) WD + DHA (WDD); 3) returned to chow + olive oil (WDChO); or 4) returned to chow + DHA (WDChD). The four treatment groups were maintained on their respective diets for 8 wks. An additional group was maintained on standard laboratory chow (Reference Diet, RD) for the 30-wk duration of the study.

resultsWhen compared to the WDB group, the WDO group displayed increased hepatic expression of genes linked to inflammation (Opn, Il1rn, Gdf15), hepatic fibrosis (collagen staining, Col1A1, Thbs2, Lox) reflecting disease progression. Mice in the WDD group, in contrast, had increased hepatic C20-22 ω3 PUFA and no evidence of NASH progression. MetS and NASH markers in the WDChO or WDChD groups were significantly attenuated and marginally different from the RD group, reflecting disease remission.

conclusionWhile these studies establish that DHA supplementation of the WD blocks WD-induced NASH progression, DHA alone does not promote full remission of diet-induced MetS or NASH.

Indexed as

AnimalsCollagen Type ICollagen Type I, alpha 1 ChainDietary FatsDiet, WesternDisease Models, AnimalDisease ProgressionDocosahexaenoic AcidsExtracellular Matrix ProteinsGene Expression RegulationGrowth Differentiation Factor 15Interleukin 1 Receptor Antagonist ProteinMaleMiceMice, Inbred C57BLMice, KnockoutCollagen Type ICollagen Type I, alpha 1 ChainDietary FatsDocosahexaenoic AcidsExtracellular Matrix ProteinsGdf15 protein, mouseGrowth Differentiation Factor 15Il1rn protein, mouseInterleukin 1 Receptor Antagonist ProteinLox protein, mouseOlive OilOsteopontinProtein-Lysine 6-OxidaseReceptors, LDLSpp1 protein, mouseThrombospondin 2Thrombospondins

Identifiers

PMID28422962
PMCPMC5396882
OpenAlexW2606378141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.